Ocular Therapeutix Stock Buy Hold or Sell Recommendation
| OCUL Stock | USD 8.83 0.31 3.64% |
Given the investment horizon of 90 days and your highly speculative risk level, our recommendation regarding Ocular Therapeutix is 'Hold'. The recommendation algorithm takes into account all of Ocular Therapeutix's available fundamental, technical, and predictive indicators you will find on this site.
Check out Ocular Therapeutix Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more information on how to buy Ocular Stock please use our How to buy in Ocular Stock guide. Note, we conduct extensive research on individual companies such as Ocular and provide practical buy, sell, or hold advice based on investors' constraints. Ocular Therapeutix. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment.
Ocular |
Execute Ocular Therapeutix Buy or Sell Advice
The Ocular recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Ocular Therapeutix. Macroaxis does not own or have any residual interests in Ocular Therapeutix or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Ocular Therapeutix's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Hold
Market Performance | Very Weak | Details | |
Volatility | Slightly risky | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Almost neglects market trends | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Ocular Therapeutix Trading Alerts and Improvement Suggestions
| Ocular Therapeutix had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 58.44 M. Net Loss for the year was (80.74 M) with loss before overhead, payroll, taxes, and interest of (6.51 M). | |
| Ocular Therapeutix currently holds about 134.54 M in cash with (70.23 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.75. | |
| Over 91.0% of the company shares are owned by institutional investors | |
| Latest headline from thelincolnianonline.com: Ocular Therapeutix Given New 15.00 Price Target at HC Wainwright |
Ocular Therapeutix Returns Distribution Density
The distribution of Ocular Therapeutix's historical returns is an attempt to chart the uncertainty of Ocular Therapeutix's future price movements. The chart of the probability distribution of Ocular Therapeutix daily returns describes the distribution of returns around its average expected value. We use Ocular Therapeutix price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Ocular Therapeutix returns is essential to provide solid investment advice for Ocular Therapeutix.
| Mean Return | -0.07 | Value At Risk | -5.33 | Potential Upside | 6.07 | Standard Deviation | 3.39 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Ocular Therapeutix historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Ocular Stock Institutional Investors
| Shares | Adage Capital Partners Gp Llc | 2024-06-30 | 3.7 M | Geode Capital Management, Llc | 2024-06-30 | 3.5 M | Perceptive Advisors Llc | 2024-09-30 | 3.3 M | Assenagon Asset Management Sa | 2024-09-30 | 2.8 M | Point72 Asset Management, L.p. | 2024-06-30 | 2.7 M | Deltec Asset Management Llc | 2024-09-30 | 2.6 M | Octagon Capital Advisors Lp | 2024-06-30 | 2.4 M | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 2.3 M | Braidwell Lp | 2024-09-30 | 2.2 M | Summer Road Llc | 2024-06-30 | 14.9 M | Vr Adviser, Llc | 2024-06-30 | 12.8 M |
Ocular Therapeutix Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change To Inventory | (737K) | (247K) | (49K) | (724K) | (331K) | (314.5K) | |
| Change In Cash | (4.5M) | 173.6M | (63.9M) | (61.9M) | 93.5M | 98.2M | |
| Free Cash Flow | (79.8M) | (54.4M) | (66.7M) | (63.3M) | (76.3M) | (72.5M) | |
| Depreciation | 2.5M | 2.8M | 2.4M | 2.1M | 3.0M | 1.8M | |
| Other Non Cash Items | 3.7M | 4.4M | 4.6M | (9.0M) | (2.9M) | (2.8M) | |
| Capital Expenditures | 2.2M | 841K | 1.2M | 3.7M | 6.1M | 6.4M | |
| Net Income | (86.4M) | (155.6M) | (6.6M) | (71.0M) | (80.7M) | (84.8M) | |
| End Period Cash Flow | 56.2M | 229.8M | 165.9M | 104.1M | 197.6M | 207.4M | |
| Investments | (2.2M) | (841K) | (1.2M) | (3.7M) | (7.8M) | (7.4M) | |
| Change Receivables | (2.3M) | (9.7M) | (8.9M) | (190K) | (171K) | (179.6K) | |
| Dividends Paid | 37.3M | 747K | 710K | 52.6M | 60.5M | 63.5M | |
| Change To Netincome | 4.5M | 93.7M | (58.5M) | 3.1M | 2.8M | 2.7M |
Ocular Therapeutix Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Ocular Therapeutix or Pharmaceuticals sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Ocular Therapeutix's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Ocular stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.26 | |
β | Beta against Dow Jones | 1.83 | |
σ | Overall volatility | 3.44 | |
Ir | Information ratio | -0.05 |
Ocular Therapeutix Volatility Alert
Ocular Therapeutix exhibits very low volatility with skewness of 0.6 and kurtosis of 1.82. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Ocular Therapeutix's stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Ocular Therapeutix's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Ocular Therapeutix Fundamentals Vs Peers
Comparing Ocular Therapeutix's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Ocular Therapeutix's direct or indirect competition across all of the common fundamentals between Ocular Therapeutix and the related equities. This way, we can detect undervalued stocks with similar characteristics as Ocular Therapeutix or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Ocular Therapeutix's fundamental indicators could also be used in its relative valuation, which is a method of valuing Ocular Therapeutix by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Ocular Therapeutix to competition |
| Fundamentals | Ocular Therapeutix | Peer Average |
| Return On Equity | -0.73 | -0.31 |
| Return On Asset | -0.22 | -0.14 |
| Profit Margin | (2.26) % | (1.27) % |
| Operating Margin | (2.65) % | (5.51) % |
| Current Valuation | 987.4 M | 16.62 B |
| Shares Outstanding | 157.22 M | 571.82 M |
| Shares Owned By Insiders | 1.00 % | 10.09 % |
| Shares Owned By Institutions | 91.07 % | 39.21 % |
| Number Of Shares Shorted | 12.67 M | 4.71 M |
| Price To Earning | (2.69) X | 28.72 X |
| Price To Book | 3.81 X | 9.51 X |
| Price To Sales | 21.92 X | 11.42 X |
| Revenue | 58.44 M | 9.43 B |
| Gross Profit | (6.51 M) | 27.38 B |
| EBITDA | (66.42 M) | 3.9 B |
| Net Income | (80.74 M) | 570.98 M |
| Cash And Equivalents | 134.54 M | 2.7 B |
| Cash Per Share | 1.75 X | 5.01 X |
| Total Debt | 83.39 M | 5.32 B |
| Debt To Equity | 0.90 % | 48.70 % |
| Current Ratio | 6.14 X | 2.16 X |
| Book Value Per Share | 0.79 X | 1.93 K |
| Cash Flow From Operations | (70.23 M) | 971.22 M |
| Short Ratio | 9.68 X | 4.00 X |
| Earnings Per Share | (1.29) X | 3.12 X |
| Target Price | 18.22 | |
| Number Of Employees | 267 | 18.84 K |
| Beta | 1.26 | -0.15 |
| Market Capitalization | 1.34 B | 19.03 B |
| Total Asset | 252.06 M | 29.47 B |
| Retained Earnings | (697.58 M) | 9.33 B |
| Working Capital | 197.34 M | 1.48 B |
| Current Asset | 106.98 M | 9.34 B |
Note: Insider Trading [view details]
Ocular Therapeutix Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Ocular . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
| Accumulation Distribution | 43394.34 | |||
| Daily Balance Of Power | 0.6596 | |||
| Rate Of Daily Change | 1.04 | |||
| Day Median Price | 8.65 | |||
| Day Typical Price | 8.71 | |||
| Price Action Indicator | 0.34 | |||
| Period Momentum Indicator | 0.31 |
About Ocular Therapeutix Buy or Sell Advice
When is the right time to buy or sell Ocular Therapeutix? Buying financial instruments such as Ocular Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Ocular Therapeutix in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Consumer Discretionary ETFs Thematic Idea Now
Consumer Discretionary ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Consumer Discretionary ETFs theme has 29 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Consumer Discretionary ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Ocular Therapeutix Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more information on how to buy Ocular Stock please use our How to buy in Ocular Stock guide.You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ocular Therapeutix. If investors know Ocular will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ocular Therapeutix listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.29) | Revenue Per Share 0.529 | Quarterly Revenue Growth 0.083 | Return On Assets (0.22) | Return On Equity (0.73) |
The market value of Ocular Therapeutix is measured differently than its book value, which is the value of Ocular that is recorded on the company's balance sheet. Investors also form their own opinion of Ocular Therapeutix's value that differs from its market value or its book value, called intrinsic value, which is Ocular Therapeutix's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ocular Therapeutix's market value can be influenced by many factors that don't directly affect Ocular Therapeutix's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ocular Therapeutix's value and its price as these two are different measures arrived at by different means. Investors typically determine if Ocular Therapeutix is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ocular Therapeutix's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.